Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
von Moos R, Plasswilm L, Zwahlen D, Meier U, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Saletti P, Rauch D, Koeberle D, Schacher S, Hayoz S, Winterhalder R, Roth A, Bodoky G, Samaras P, Berger M, Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). Eur J Cancer 2017; 89:82-89.
11.12.2017
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
11.12.2017
Eur J Cancer 2017; 89:82-89
von Moos Roger, Plasswilm Ludwig, Zwahlen Daniel, Meier Urs R, Yan Pu, Izzo Paola, Klingbiel Dirk, Bärtschi Daniela, Zaugg Kathrin, Saletti Piercarlo, Rauch Daniel, Koeberle Dieter, Schacher Sabina, Hayoz Stefanie, Winterhalder Ralph C, Roth Arnaud, Bodoky György, Samaras Panagiotis, Berger Martin D, Swiss Group for Clinical Cancer Research (SAKK)
Weiter
